Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shumian capsule (舒眠胶囊) is a proprietary Chinese medicine (TCM) primarily developed and manufactured by Guizhou Bailing Group Pharmaceutical. It is indicated for the treatment of insomnia, anxiety, and depressive disorders, particularly those characterized by liver qi stagnation and internal heat. The formulation is a combination of several botanical extracts, including *Ziziphus jujuba* var. *spinosa* (Suanzaoren), *Albizia julibrissin* (Hehuanhua), *Salvia miltiorrhiza* (Danshen), and *Bupleurum chinense* (Chaihu). These ingredients are traditionally used to soothe the liver, clear heat, and calm the spirit (Anshen). In the context of the COVID-19 pandemic, Shumian capsule has been investigated in clinical trials to evaluate its efficacy in managing sleep and mood disorders in convalescent patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shumian capsule.